Oncology Molecular Diagnostic Market Size, Share Report By 2033

The global oncology molecular diagnostic market size is expected to increase USD 7.71 billion by 2033 from USD 2.45 billion in 2022 with a CAGR of 12.20% between 2024 and 2033.

Key Takeaways

  • North America contributed more than 41% of the market share in 2023.
  • Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
  • By type, the breast cancer segment generated over 22% of the market share in 2023.
  • By type, the liver cancer segment is anticipated to grow at a remarkable CAGR of 13.9% between 2024 and 2033.
  • By technology, the polymerase chain reaction (PCR) segment generated over 32% of the market share in 2023.
  • By technology, the sequencing segment is expected to expand at the fastest CAGR over the projected period.
  • By product, the reagents segment generated over 59% of market share in 2023.
  • By product, the instruments segment is expected to expand at the fastest CAGR over the projected period.
Oncology Molecular Diagnostic Market Size 2024 To 2033

The Oncology Molecular Diagnostic Market is a dynamic sector within the broader healthcare industry focused on the application of molecular biology techniques to diagnose and monitor various types of cancer. Molecular diagnostics involve the analysis of genetic material at the molecular level, enabling precise identification of genetic mutations and alterations associated with cancer. This market plays a crucial role in personalized medicine, tailoring treatment plans based on the specific genetic characteristics of an individual’s cancer.

Growth Factors:

The market’s growth is propelled by advancements in genomics, increasing cancer prevalence, and the rising demand for targeted therapies. Molecular diagnostics offer faster and more accurate cancer diagnosis compared to traditional methods, driving their adoption. Additionally, ongoing research and development activities in the field contribute to the introduction of innovative diagnostic technologies, further fueling market expansion. The push towards personalized medicine and the integration of artificial intelligence in diagnostics are also significant growth factors.

Get a Sample: https://www.precedenceresearch.com/sample/3677


A notable trend in the Oncology Molecular Diagnostic Market is the shift towards liquid biopsy techniques, allowing for non-invasive cancer detection through the analysis of circulating tumor DNA (ctDNA) or other biomarkers in blood samples. Integration of next-generation sequencing (NGS) technologies is another prevalent trend, providing a comprehensive view of the cancer genome. Moreover, there is a growing emphasis on companion diagnostics, where molecular diagnostics play a pivotal role in identifying patients who are likely to respond positively to specific targeted therapies.


The market exhibits regional variations influenced by factors such as healthcare infrastructure, technological adoption, and prevalence of cancer. North America and Europe are prominent regions, driven by well-established healthcare systems and a high prevalence of cancer. Asia-Pacific is witnessing significant growth, attributed to increasing awareness, improving healthcare infrastructure, and rising cancer incidence. Developing regions in Latin America and Africa are also expected to contribute to the market’s growth as healthcare accessibility improves.

Oncology Molecular Diagnostic Market  Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 12.20%
Global Market Size in 2023 USD 2.45 Billion
Global Market Size by 2033 USD 7.71 Billion
U.S. Market Size in 2023 USD 0.70 Billion
U.S. Market Size by 2033 USD 2.25 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type, By Technology and By Product
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


The market is segmented by the type of molecular diagnostics utilized in oncology. This includes various diagnostic methodologies such as polymerase chain reaction (PCR), in-situ hybridization, next-generation sequencing (NGS), immunohistochemistry, and others. Each type of diagnostic method provides unique insights into the molecular characteristics of cancer cells, enabling healthcare professionals to tailor treatment strategies based on specific genetic and molecular profiles.


Technological advancements have significantly influenced the landscape of oncology molecular diagnostics. The market is divided based on the technology platforms employed in the analysis of cancer biomarkers. Next-generation sequencing (NGS) stands out as a high-throughput technology that allows for comprehensive genomic profiling, while polymerase chain reaction (PCR) remains a widely used technique for amplifying and detecting specific DNA sequences. Other technologies, such as microarrays and mass spectrometry, also play essential roles in molecular diagnostics, contributing to the depth and accuracy of cancer characterization.


The product segment encompasses the various tools and resources essential for conducting molecular diagnostics in oncology. This includes diagnostic kits, reagents, instruments, and software solutions. Diagnostic kits often contain the necessary components for detecting specific biomarkers, while instruments are designed to facilitate the processing and analysis of molecular data. Companion diagnostics, a subset of products, have gained prominence by assisting in the identification of patients who are most likely to respond positively to targeted therapies. The continuous development of innovative products underscores the market’s commitment to providing healthcare professionals with advanced tools for precise cancer diagnosis and treatment planning.

Read Also: Flexitank Market Size To Rise USD 10.25 Billion By 2033

Recent Developments in the Oncology Molecular Diagnostic Market

  • In December 2020, Veracyte Inc. and Bayer AG initiated a collaboration to enhance the Precision Oncology Patient Identification Program, specifically focusing on thyroid cancer. This partnership aims to utilize Veracyte’s Afirma Xpression Atlas (XA) for testing, identifying genomic drivers in tumor cells. The program is anticipated to benefit patients with advanced thyroid cancer by enabling personalized treatment strategies based on biomarker-driven therapies.
  • In February 2020, Danaher, through its subsidiary Cepheid, announced a collaboration with Sherlock Biosciences to explore the development of innovative molecular diagnostic tests using CRISPR technology. The focus of this collaboration extends to oncology and infectious diseases, signaling a joint effort to advance groundbreaking diagnostic solutions for improved patient care and disease management.

Competitive Landscape:

The Oncology Molecular Diagnostic Market features a competitive landscape with several key players vying for market share. Companies invest heavily in research and development to introduce innovative diagnostic solutions. Major players often engage in strategic collaborations and partnerships to enhance their product portfolios and expand their global presence. Notable players in the market include Roche Diagnostics, Qiagen, Thermo Fisher Scientific, Illumina, and Abbott Laboratories, among others. Continuous technological advancements, regulatory approvals, and a focus on customer-centric solutions characterize the competitive strategies within this dynamic market.

Oncology Molecular Diagnostic Market Companies

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Myriad Genetics, Inc.
  • Agilent Technologies, Inc.
  • Siemens Healthineers
  • Danaher Corporation (Cepheid)
  • Sysmex Corporation
  • Hologic, Inc.
  • Guardant Health, Inc.
  • Foundation Medicine, Inc.

Segments Covered in the Report:

By Type

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Other Cancer

By Technology

  • PCR
  • In Situ Hybridization
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • TMA
  • Others

By Product

  • Instruments
  • Reagents
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Fabio Thomas 

Fabio Thomas 

Fabio is a Senior Editor at Reports Gazette who focused on healthcare it news. Also, he is a writer and public health researcher.  He joins Reports Gazette from Modern Healthcare, where he worked as a web producer since 2020. Before joining the Modern Healthcare team, Fabio received a master’s degree in journalism from Northwestern University. He is the author of a 2016-17 book, he is also the recipient of numerous awards.

View all posts by Fabio Thomas  →

Leave a Reply

Your email address will not be published. Required fields are marked *